ROR gamma (RORγ) modulators

Patent metadata

Field	Value
Publication number	US-11299456-B2
Application number	US-201916710782-A
Country	US
Kind code	B2
Filing date	Dec 11, 2019
Priority date	Dec 5, 2016
Publication date	Apr 12, 2022
Grant date	Apr 12, 2022

Abstract

The present application relates to compounds according to (Formula IA) or (Formula IB):

or a pharmaceutically acceptable salt thereof.

The compounds can be used as inhibitors of RORγ and are useful for the treatment of RORγ mediated diseases.

First claim

The invention claimed is:

1. A pharmaceutical composition in unit dosage form for oral or parenteral administration, said pharmaceutical composition comprising:
a compound having the absolute configuration corresponding to Formula IA 2-{4-[(cyclopropylmethyl)sulfonyl]phenyl}-N-{4-[(1R)-1-(difluoromethyl)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}acetamide:

or a pharmaceutically acceptable salt thereof; and,
one or more pharmaceutically acceptable excipients.

2. A process of preparing a compound of Formula (IA) comprising:
i) obtaining 2-(4-bromophenyl)-1,1,1,3,3-pentafluoro-propan-2-ol (IV) from 1-(4-bromophenyl)-2,2-fluoro-ethanone (V) by trifluoromethylation using trifluoromethyltrimethylsilane (TMSCF 3 ) in the presence of tetra-N-butylammonium fluoride (TBAF):

ii) obtaining a compound of Formula (II) by amine substitution of the bromine atom of 2-(4-bromophenyl)-1,1,1,3,3-pentafluoro-propan-2-ol (IV):

wherein said substitution is performed using lithium bis(trimethylsilyl)amide), 2-(dicyclohexylphosphino)biphenyl and tris(dibenzylidene acetone)dipalladium;
iii) reacting said amine of formula (II) with a compound of Formula (III):

to give the compound of Formula (I);

wherein said reaction is performed in the presence of 1-propanephosphonic anhydride and N,N-diisopropylethylamine; and,
iv) obtaining the compound of Formula (IA) by chiral separation

3. A method for treatment of at least one condition selected from the group consisting of multiple sclerosis, inflammatory bowel disease, Crohn's disease, psoriasis, rheumatoid arthritis, asthma, osteoarthritis, Kawasaki disease, Hashimoto's thyroiditis and mucosal leishmaniasis,
said method comprising administering to a person in need of the treatment a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and from 0.0001-100 mg per kilogram of bodyweight of a compound having the absolute configuration corresponding to Formula IA or a pharmaceutically acceptable salt thereof, wherein Formula IA is 2-{4-[(cyclopropylmethyl)sulfonyl]phenyl}-N-{4-[(1R)-1-(difluoromethyl)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}acetamide:

4. The method according to claim 3 , wherein the at least one condition is selected from the group consisting of rheumatoid arthritis, psoriasis, inflammatory bowel disease, Crohn's disease and multiple sclerosis.

5. The method according to claim 3 , wherein the at least one condition is selected from osteoarthritis and asthma.

6. The method according to claim 3 , wherein the at least one condition is mucosal leishmaniasis.

Assignees

• Lead Pharma Holding Bv
• Sanofi Sa

Inventors

• Cals Joseph Maria Gerardus Barbara
• Machnik David
• Nabuurs Sander Bernardus
• Sabuco Jean-Francois

Classifications

• A61P17/00 Primary

  Drugs for dermatological disorders · CPC title

• C07C317/46

  the carbon skeleton being further substituted by singly-bound oxygen atoms · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07C317/50 Primary

  at least one of the nitrogen atoms being part of any of the groups [IMAGE cpc-sch-C07C-0976.gif], X being a hetero atom, Y being any atom · CPC title